CARLSBAD, Calif., Dec. 6 /PRNewswire/ -- Medinox announced today that George Ko, Ph.D., 70, has been appointed to the Company's board of directors. Dr. Ko is currently Chairman and CEO of Taiwan Biotech Company, Taiwan Venture Capital, Ltd., and Evergene Biotech Inc in Taiwan. Dr. Ko holds board positions at Mission Healthcare Technologies, Inc., Formosan Union Chemical Corp., First Taiwan Venture Capital, Inc., F. R. Venture Capital, Inc. and Jipa Investment Co, Ltd.
"We are pleased that Dr. George Ko has agreed to join our board of directors," commented Dr. Monte Lai, the Company's President and CEO. "In light of our strategy to conduct clinical trials in Asia, Dr. Ko's strength in developing businesses in those markets will be helpful to the board and management as we move that strategy forward."
Medinox is the leader in anti-NO therapeutics and is developing a broad technology platform to address a wide variety of unmet medical needs including septic shock, acute respiratory distress syndrome (including SARS) and hemorrhagic shock. In addition to its NO technology, Medinox is also developing new and safer NSAID prodrugs and MX-1520, a unique therapeutic for sickle cell anemia. For information about Medinox and its products, please visit the Company's website at http://www.medinox.com/, or contact Monte Lai, Ph.D., President & CEO of Medinox, Inc., at 760.603.8989, or by email at email@example.com.
CONTACT: Monte Lai, Ph.D., President & CEO of Medinox, Inc.,+1-760-603-8989, firstname.lastname@example.org